Related Experiment Videos
Coagulation abnormalities in women taking oral contraceptives
JAMA
|February 28, 1977
Summary
Oral contraceptives (OCs) did not affect platelet aggregation but altered coagulation pathways. Elevated heavy molecular weight fibrinogen derivatives suggest plasma coagulation abnormalities, not platelet changes, may increase thromboembolic risk in women using OCs.
Area of Science:
- Hematology
- Pharmacology
- Thrombosis Research
Background:
- Oral contraceptives (OCs) are widely used by women of reproductive age.
- Previous studies suggest a link between OCs and an increased risk of thromboembolic disorders.
- The precise mechanisms underlying this association remain incompletely understood.
Purpose of the Study:
- To investigate the effects of OCs on platelet function and plasma coagulation in asymptomatic women.
- To identify potential hemostatic markers associated with OC use and thromboembolic risk.
Main Methods:
- Comparison of platelet aggregation and serotonin release in women on OCs versus controls.
- Evaluation of intrinsic coagulation pathway activation markers: factor XII, prekallikrein, and kallikrein inhibitors.
- Measurement of heavy molecular weight fibrinogen derivatives (HMWFD) and fibrin/fibrinogen degradation products.
Main Results:
- Platelet aggregation and serotonin release were not significantly different between OC users and controls.
- Women on OCs showed normal factor XII, moderately elevated prekallikrein, and decreased kallikrein inhibitor levels.
- A significant elevation in HMWFD concentration (P < .001) and a decrease in serum fibrin/fibrinogen degradation products (P < .05) were observed in OC users.
Conclusions:
- The observed coagulation profile in OC users suggests activation of the coagulation system independent of factor XII activation or decreased antithrombin III.
- Increased HMWFD concentration points towards plasma coagulation abnormalities as a potential mechanism for increased thromboembolic risk.
- Findings implicate plasma coagulation alterations, rather than platelet changes, as a key factor in the predisposition to thromboembolic disorders associated with oral contraceptive use.